Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) decreased during the last reporting period, falling from 4.14M to 3.97M. This put 10.76% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Please provide your email address to receive an email when new articles are posted on . Bipolar disorder and postpartum symptoms often overlap among women, leading to bipolar 1 being ...

of Supernus Pharmaceuticals, Inc. Read also: Lupin Launches Ajaduo M Forte, a Triple Fixed-Dose Combination of Empagliflozin, Linagliptin, and Metformin Extended Release (ER) Lupin Limited is a global ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target of $36.00. Protect Your Portfolio ...

President and CEO of Supernus. “In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s ...

Early in the second quarter, we launched ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...

The launch of ONAPGO, a new growth product for Parkinson's disease, has shown encouraging initial responses from physicians. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has a strong balance sheet ...